TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06048874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Study: NCT03733678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for SARCs
Description: SARCs are offered free to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client
Study: NCT04802057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088
Description: Pharmaceutical form: solution for injection~Route of administration: IV and SC (Part 1) IV (Part 2)
Study: NCT06009796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Tissue Borne Rapid Palatal Expansion
Description: In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Tissue Borne Rapid Palatal Expansion
Description: In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Bone Borne Rapid Palatal Expansion
Description: After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
Study: NCT05139563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo injection: Intralipid 20% fat emulsion
Description: placebo intralipid 20% intramuscular (IM) injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo injection: Intralipid 20% fat emulsion
Description: placebo intralipid 20% intramuscular (IM) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo implant
Description: placebo subdermal implant rod

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo implant
Description: placebo subdermal implant rod
Study: NCT05137093

Intervention type: DEVICE
Intervention: Actigraphy Device
Description: Patients will wear actigraphy device which detects scratching events.

Intervention type: DEVICE
Intervention: Actigraphy Device
Description: Patients will wear actigraphy device which detects scratching events.
Study: NCT06102863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
Description: Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
Study: NCT05398497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation will be performed under ultrasound guidance.
Study: NCT06266741

Intervention type: DIAGNOSTIC_TEST
Intervention: Lubricin
Description: Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lubricin
Description: Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
Study: NCT06188663

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt supplementation (encapsulated sodium chloride)
Description: A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
Study: NCT05496868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin 600mg
Description: Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo tablets. Administered crushed through nasogastric tube with the same schedule as reparixin as add-on to the standard of care. After extubation and if the patient can swallow placebo may be administered orally.~Total duration of the treatment: 14 days
Study: NCT05540717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PQ Grass
Description: Suspension for Injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study: NCT05781386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM1811-03 or in combination with Sintilimab injectiont
Description: SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)
Study: NCT05321914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
Study: NCT06310590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT6003 Injection
Description: Selective internal radiation therapy (SIRT) with Yttrium-90 carbon microspheres
Study: NCT04899505

Intervention type: OTHER
Intervention: Evaluation on appearance of unpleasant body odors
Description: Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.
Study: NCT04902170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge pars plana vitrectomy
Description: 25 gauge pars plana vitrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25 gauge pars plana vitrectomy
Description: 25 gauge pars plana vitrectomy
Study: NCT03733678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client
Study: NCT06311929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody and lenvatinib
Description: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 monoclonal antibody
Description: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
Study: NCT03733678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price discounts for LARCs
Description: LARCs are offered at lower prices to the client
Study: NCT06404554

Intervention type: OTHER
Intervention: without any intervention
Description: without any intervention

Intervention type: OTHER
Intervention: without any intervention
Description: without any intervention
Study: NCT03733678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously
Study: NCT05803551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous 0.9% saline infusions for three consecutive days.
Study: NCT03733678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential vs. simultaneous recommendations
Description: Top ranked methods are presented to the client sequentially or simultaneously
Study: NCT05240586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
Study: NCT05862805

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sample Collection and Endometrial Biopsy
Description: Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sample Collection and Endometrial Biopsy
Description: Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
Study: NCT05054777

Intervention type: PROCEDURE
Intervention: oncoplastic breast-conserving surgery
Description: The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques

Intervention type: PROCEDURE
Intervention: conventional breast-conserving surgery
Description: conventional breast-conserving surgery without any oncoplastic operations
Study: NCT04824872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, low dose
Study: NCT05270499

Intervention type: DEVICE
Intervention: Aveir VR Leadless Pacemaker System
Description: This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.
Study: NCT04824872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, low dose
Study: NCT05845723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
Study: NCT06485284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: El Camino
Description: El Camino is a goal-setting sexual health promotion program. El Camino's lessons and activities:~* Are anchored in sexual health promotion and goal-setting~* Incorporate a goal achievement model throughout the curriculum~* Are designed with a focus on the needs of Latino youth~* Focus on the most effective forms of contraception, including long-acting reversible contraceptives~The El Camino curriculum contains eleven 45-minute lessons and is divided into three sections, or arcs. The three arcs focus on goal setting, sexual and reproductive health, and healthy relationships.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life skills program
Description: Youth enrolled in the control condition will receive one of several curricula focused on life skills or leadership, depending on the site and implementation period. These curricula include PODER, an 11-session curriculum that focuses on youth leadership development; Youth Encuentros, a psychoeducational curriculum focused on mental health; El Joven Noble, a youth leadership curriculum; and Courageous Queens, a socio-emotional and character strengthening curriculum.
Study: NCT06235970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (tES) including SHAM
Description: Transcranial electrical stimulation, known as tES, refers to a family of devices that utilize low-cost technologies and involve low-intensity currents which are safe for humans, and carry minimal risk of side effects or adverse events. Conventional approaches, which utilize fixed direct currents (tDCS) or alternating currents at a fixed oscillatory frequency (tACS), have been widely used as both a basic research tool and as a clinical intervention. In the current project, we use a custom-built device that enables near real-time current modulation triggered digitally, via software control, to allow for stimulation protocols guided by whole-brain individualized neural modeling.
Study: NCT04824872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for dasiglucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for dasiglucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for dasiglucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for dasiglucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for dasiglucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for dasiglucagon
Study: NCT05240586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy, medication(prn)
Description: This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
Study: NCT06400563

Intervention type: DEVICE
Group type: OTHER
Intervention: MRg-NIRS
Description: The trial tests the investigator designed and developed Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) imaging system for breast cancer detection. The wearable NIRS imaging system uses 8 flex circuit strips, each with six photo-detectors (PDs) and six source fibers, that are ready to attach to a breast radially by using an adhesive nipple cover and breast tape.
Study: NCT05311085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine
Description: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine delivered via an e-cigarette
Description: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine plus nicotine delivered via an e-cigarette
Description: Cytisine: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
Study: NCT05089305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone plasma
Description: Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).